Research programme: IgE synthesis inhibitors - Pfizer

Drug Profile

Research programme: IgE synthesis inhibitors - Pfizer

Alternative Names: Research programme: IgE secretion inhibitors - Pfizer; Research programme: interleukin-4 pathway inhibitors - Pfizer

Latest Information Update: 13 Mar 2008

Price : $50

At a glance

  • Originator Pfizer
  • Class Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Allergic asthma; Hypersensitivity

Most Recent Events

  • 06 Sep 2004 Data presented at the 18th International Symposium of Medicinal Chemistry (ISMC-2004) have been added to the adverse events and Obstructive Airways Disease pharmacodynamics sections
  • 07 Oct 2003 The drug targets accepted by Pfizer have entered the compound screening phase at Pfizer
  • 26 Jun 2002 Rigel Pharmaceuticals has concluded its research collaboration with Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top